selective RET kinase inhibitor
Retevmo Delivers Clinically Meaningful Event‑Free Survival in Phase 3 Trial
Eli Lilly and Company (NYSE:LLY) announced positive topline results from its Phase 3 LIBRETTO‑432 trial, evaluating Retevmo (selpercatinib) as adjuvant therapy in patients with early‑stage RET fusion‑positive non‑small cell lung cancer (NSCLC). The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in event‑free survival compared to placebo. Trial highlights Overall…
